<DOC>
	<DOCNO>NCT02283320</DOCNO>
	<brief_summary>BIND-014 ( docetaxel nanoparticles injectable suspension ) study patient v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ( KRAS ) mutation positive squamous cell non-small cell lung cancer ( NSCLC ) progress treatment one prior platinum-containing chemotherapy regimen .</brief_summary>
	<brief_title>A Study BIND-014 ( Docetaxel Nanoparticles Injectable Suspension ) Second-line Therapy Patients With KRAS Positive Squamous Cell Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Males female least 18 year age Diagnosis NSCLC locally advance metastatic disease Positive KRAS mutation Squamous cell histology Previously treat one platinumbased chemotherapy Disease status must measurable and/or evaluable disease Performance status 0 1 ECOG Scale Prior chemotherapy complete least 3 week prior study enrollment Prior radiation therapy allow &lt; 25 % bone marrow Patient compliance geographic proximity allow adequate followup Adequate organ function Patients reproductive potential must use contraceptive method Signed informed consent patient Active infection Pregnancy planning become pregnant Breast feeding Serious concomitant systemic disorder Second primary malignancy Patients symptomatic brain metastasis Presence detectable ( physical exam ) thirdspace fluid collection More 1 prior cytotoxic chemotherapy regimen advance disease Prior treatment docetaxel History severe hypersensitivity reaction polysorbate 80 Peripheral neuropathy study entry Patients know HIV positive Patients know seropositive hepatitis C hepatitis B Congenital long QT syndrome , congestive heart failure , bradyarrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>